This compound is a critical chiral intermediate for synthesizing Levofloxacin, a widely used fluoroquinolone antibiotic. It serves as the core structural precursor, providing the (S)-configured difluoro-benzoxazine carboxylic acid moiety essential for Levofloxacin’s antibacterial activity. Its high enantiomeric purity guarantees the correct stereochemistry of the final drug, directly ensuring therapeutic efficacy and safety. Beyond API synthesis, it acts as a reference standard in HPLC quality control for Levofloxacin and related fluoroquinolones, supporting GMP-compliant manufacturing. In pharmaceutical research, it is used to develop novel fluoroquinolone derivatives with improved potency or safety profiles. Due to its stable crystalline form and well-defined reactivity, it is indispensable in both industrial production and academic studies of antibacterial agents.
Classified as GHS07 (Warning) with mild hazards: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). No acute oral toxicity data (LD?? >2000 mg/kg, rat), indicating low acute toxicity. Inhalation of dust may irritate the respiratory tract, causing cough or throat discomfort. Skin contact may lead to redness, itching, or mild dermatitis, especially with prolonged exposure. Eye contact can cause stinging, tearing, and conjunctival inflammation. It is non-flammable but may decompose under strong heat, releasing toxic fluoride fumes. Handle in well-ventilated fume hoods, wearing nitrile gloves, safety goggles, and dust masks. In case of skin contact, rinse with plenty of water for 15 minutes; for eye contact, flush with water and seek medical help. Store in cool, dry, dark areas away from heat and strong oxidants. Dispose as hazardous waste per local regulations.
